文献速递临床试验与 GCP流行病学与生物统计

环丙沙星单药对比链霉素联合环丙沙星治疗腺鼠疫的非劣效性随机试验方案

An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial.
PubMed 文献 · Trials · 2020-08-17

IMASOY试验为开放标签、随机、非劣效性对照试验,在马达加斯加五个地区招募疑似腺鼠疫或肺鼠疫患者,比较两种10天方案:环丙沙星单药与链霉素后接环丙沙星。主要终点为第11天腺鼠疫患者的治疗反应比例。该试验旨在为鼠疫治疗指南提供随机对照证据。

要点

  • 比较环丙沙星单药与链霉素联合环丙沙星治疗腺鼠疫的10天方案。
  • 主要终点为第11天治疗反应比例,采用非劣效性设计。
  • 若成功,可避免使用注射用潜在毒性氨基糖苷类。

核心结论

  • 试验假设环丙沙星单药治疗腺鼠疫不劣于链霉素后接环丙沙星,从而避免使用注射用潜在毒性氨基糖苷类。

研究设计与样本

  • 两臂平行组随机对照试验,在马达加斯加五个地区的 peripheral health centres 开展。
  • 招募所有年龄的男性和非孕妇,疑似腺鼠疫或肺鼠疫,跨越三个鼠疫季节。
  • 试验注册于 ClinicalTrials.gov NCT04110340,2019年10月1日注册,预计2022年完成招募。

关键数值与推荐

  • 两种方案均为10天疗程,均纳入马达加斯加国家指南。
  • 主要终点为第11天评估的腺鼠疫患者治疗反应比例,治疗反应定义为存活、发热消退、可测量淋巴结肿大缩小25%、未接受替代治疗且无继续抗生素的临床决定。

临床怎么用

  • 若试验达到非劣效性,环丙沙星单药可能成为腺鼠疫的治疗选择,避免注射链霉素。
  • 结果可能影响马达加斯加及其他鼠疫流行国家的诊疗指南。

局限性

  • 试验方案尚未报告结果,目前无法评估疗效与安全性。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bubonic plague is the primary manifestation of infection with Yersinia pestis, accounting for 90% of all plague cases and with 75% of global cases reported in Madagascar. All drugs in use for treating plague are registered based on experimental data and anecdotal evidence, and no regimen currently recommended is supported by a randomized clinical trial. The IMASOY trial intends to fill this knowledge gap by comparing two 10-day regimens included in the national guidelines in Madagascar. The primary objective of the trial is to test the hypothesis that ciprofloxacin monotherapy is non-inferior to streptomycin followed by ciprofloxacin for the treatment of bubonic plague, thus avoiding the need for injectable, potentially toxic, aminoglycosides. METHODS: A two-arm parallel-group randomized control trial will be conducted across peripheral health centres in Madagascar in five districts. Males and non-pregnant females of all ages with suspected bubonic or pneumonic plague will be recruited over the course of three plague 'seasons'. The primary endpoint of the trial is to assess the proportion of patients with bubonic plague who have a therapeutic response to treatment (defined as alive, resolution of fever, 25% reduction in the size of measurable buboes, has not received an alternative treatment and no clinical decision to continue antibiotics) as assessed on day 11. DISCUSSION: If successful, the trial has the potential to inform the standard of care guidelines not just in Madagascar but in other countries afflicted by plague. The trial is currently ongoing and expected to complete recruitment in 2022. TRIAL REGISTRATION: ClinicalTrials.gov NCT04110340 . Registered on 1 October 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Randremanana RV, Raberahona M, Randria MJD, et al. An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial. Trials. 2020. PMID: 32807214. doi:10.1186/s13063-020-04642-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。